Form 8-K - Current report:
SEC Accession No. 0001999371-25-009455
Filing Date
2025-07-21
Accepted
2025-07-21 07:05:28
Documents
13
Period of Report
2025-07-21
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT tonix-8k_071725.htm   iXBRL 8-K 28238
2 PRESS RELEASE OF THE COMPANY, JULY 17, 2025 ex99-01.htm EX-99.01 8969
  Complete submission text file 0001999371-25-009455.txt   205522

Data Files

Seq Description Document Type Size
3 XBRL LABEL FILE tnxp-20250721_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE tnxp-20250721_pre.xml EX-101.PRE 22364
5 XBRL SCHEMA FILE tnxp-20250721.xsd EX-101.SCH 3023
16 EXTRACTED XBRL INSTANCE DOCUMENT tonix-8k_071725_htm.xml XML 3549
Mailing Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928
Business Address 26 MAIN STREET, SUITE 101 CHATHAM NJ 07928 212-980-9155
Tonix Pharmaceuticals Holding Corp. (Filer) CIK: 0001430306 (see all company filings)

EIN.: 261434750 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36019 | Film No.: 251135691
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)